Aurinia Pharmaceuticals stock heads toward its November 3 report

Published on 10/08/2026 at 04:39 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Aurinia Pharmaceuticals earned USD 0.28 per share in Q2 2026, above the USD 0.19 consensus. Revenue reached USD 83.2 million.

AUR, CA05156V1022, Illustration mit AI erstellt.

Aurinia Pharmaceuticals stock (ISIN CA05156V1022) has its next reported checkpoint on November 3, 2026, when the company is scheduled to publish third-quarter results. MarketBeat lists the report before market open, with an 8:30 a.m. ET conference call.

Q2 earnings set the baseline

For the quarter ended June 30, 2026, Aurinia reported USD 83.2 million in revenue and USD 37.4 million in net income. Yahoo Finance said revenue increased 19 percent year over year, while net income rose 74 percent.

The quarter also produced diluted earnings of USD 0.28 per share, above the USD 0.19 consensus cited by Zacks. That comparison gives the November report a clear test: investors will be measuring earnings against a quarter that already exceeded expectations.

Guidance meets analyst expectations

Aurinia reiterated 2026 guidance of USD 315 million to USD 325 million in total revenue and USD 305 million to USD 315 million in net product sales, according to Yahoo Finance. The ranges make the next report more important than a single quarterly beat because full-year delivery remains the central operating measure.

MarketBeat reports a Moderate Buy consensus from six analysts, with an average target of USD 17.67. Against the USD 16.01 Nasdaq close on October 7, 2026, that target stands 10.4 percent above the stock price.

Nasdaq close remains below yearly high

Aurinia operates as a biopharmaceutical company focused on autoimmune diseases, with LUPKYNIS as its FDA-approved oral therapy for active lupus nephritis. The company also develops aritinercept, a dual inhibitor aimed at potential autoimmune-disease applications, as described on its investor page.

Aurinia closed at USD 16.01 on Nasdaq on October 7, 2026, up 2.04 percent from the prior close. The session range was USD 15.50 to USD 16.15, while the 52-week range was USD 10.90 to USD 19.25 and volume reached 682,527 shares.

Market value ahead of the report

The stock's market capitalization was USD 2.1 billion as of October 7, 2026. The November 3 report will show whether the second-quarter combination of revenue growth, earnings expansion and reiterated guidance is carrying into the September quarter.